The Week Ahead: May 4 – May 8, 2026

Posted on | by Leon Hinde | Leave a Comment on The Week Ahead: May 4 – May 8, 2026

The Week Ahead: May 4 – May 8, 2026

The upcoming week will be dominated by central bank policy and the tail-end of the US earnings season. Investors should focus on the following key events:

1. Macro Data and Central Banks

  • RBA Interest Rate Decision: The market is bracing for a possible 25 basis point (bps) rate hike from the Reserve Bank next week. Persistent cost pressures and the March inflation print of 4.6% have led analysts to forecast that rates could rise to 4.60% by September 2026.
  • US Fed Watch: With the Fed Funds Interest Rate currently at 3.75%, any commentary following the recent PCE data will be scrutinized for signs of a pivot or continued pause.

2. Company Events and Earnings

ASX Resource Reports: Following BHP’s recent Quarterly Activities Report, market participants will be looking for production guidance updates from mid-tier miners as commodity price volatility continues.

US Earnings: The earnings season continues with key players in the energy and consumer discretionary sectors scheduled to report. The focus will remain on whether corporate margins can continue to withstand higher interest costs.

CSL

Posted on | by Leon Hinde | Leave a Comment on CSL

CSL is navigating a period of significant structural transition and market re-evaluation. The stock recently hit a nine-year low, primarily driven by a sharp earnings reset in its half-year results and broader regulatory headwinds.

Valuation: The price-to-earnings (P/E) ratio has compressed to approximately 15x (TTM) on an underlying basis.

Recent Financial Performance (H1 FY26)
The company’s February 2026 earnings report was a major catalyst for the recent sell-off:

  • Net Profit Plunge: Reported Net Profit After Tax (NPAT) fell 81% to US$401 million, largely due to ~US$1.1 billion in one-off restructuring charges and asset impairments.
  • Underlying Performance: Underlying NPATA fell 7% to US$1.9 billion.
  • Revenue: Declined 4% to US$8.3 billion (constant currency). The core CSL Behring plasma division saw a 7% sales contraction, driven by U.S. Medicare reimbursement reforms and policy changes in China affecting pricing.
  • Impairments: Significant write-downs were taken on CSL Vifor (primarily due to generic competition for its iron therapy, Venofer®) and intellectual property within CSL Seqirus.

Strategic Developments & Recovery Plan
Despite the earnings volatility, management is aggressively deploying capital to stabilize margins:

  • Capacity Expansion: In March 2026, CSL broke ground on a US$1.5 billion expansion of its Kankakee, Illinois facility. This project will utilize “Horizon 2” technology designed to increase protein yield from plasma.
  • Share Buy-back: CSL is currently active in an on-market share buy-back program. As of today, April 27, 2026, the company has repurchased nearly 6 million shares to support shareholder value.
  • Cost Savings: CSL has targeted US$500M+ in annual pre-tax savings by FY28 through organizational simplification.
  • Vaccine Pipeline: CSL Seqirus recently secured new long-term contracts with the Pan American Health Organization (PAHO) and Canada for pandemic influenza preparedness.

Dividends & Guidance

  • Dividends: The interim dividend of US$1.30 per share (unfranked) was paid on April 8, 2026. The current annual yield sits at approximately 3.3%.
  • FY26 Outlook: Management has maintained guidance for the full year 2026, expecting 2–3% revenue growth and 4–7% NPATA growth (excluding one-offs). However, the market remains cautious about the “structural” nature of margin pressures through FY28.

Investor Outlook
The current market sentiment is a battle between value seekers (pointing to “oversold” technical indicators and a 15-year low multiple) and skeptics concerned about the long-term impact of U.S. Medicare drug price negotiations and competition in the iron deficiency market.